Clinical Trial Update: Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy [Phase 1]

View source ↗

Summary

Phase 1 dose-finding study of HCD122 in Chronic Lymphocytic Leukemia patients who relapsed or failed prior fludarabine therapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• HCD122

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: TERMINATED